Cargando…

Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Heiduk, Max, Plesca, Ioana, Glück, Jessica, Müller, Luise, Digomann, David, Reiche, Charlotte, von Renesse, Janusz, Decker, Rahel, Kahlert, Christoph, Sommer, Ulrich, Aust, Daniela E., Schmitz, Marc, Weitz, Jürgen, Seifert, Lena, Seifert, Adrian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/
https://www.ncbi.nlm.nih.gov/pubmed/36509285
http://dx.doi.org/10.1172/jci.insight.152761
_version_ 1784849446018744320
author Heiduk, Max
Plesca, Ioana
Glück, Jessica
Müller, Luise
Digomann, David
Reiche, Charlotte
von Renesse, Janusz
Decker, Rahel
Kahlert, Christoph
Sommer, Ulrich
Aust, Daniela E.
Schmitz, Marc
Weitz, Jürgen
Seifert, Lena
Seifert, Adrian M.
author_facet Heiduk, Max
Plesca, Ioana
Glück, Jessica
Müller, Luise
Digomann, David
Reiche, Charlotte
von Renesse, Janusz
Decker, Rahel
Kahlert, Christoph
Sommer, Ulrich
Aust, Daniela E.
Schmitz, Marc
Weitz, Jürgen
Seifert, Lena
Seifert, Adrian M.
author_sort Heiduk, Max
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects of neoadjuvant chemotherapy on the cytokine production of tumor-infiltrating T cells are unknown in PDAC. METHODS: We performed multiplex immunofluorescence to investigate T cell infiltration in 91 patients with PDAC. Using flow cytometry, we analyzed tumor and matched blood samples from 71 patients with PDAC and determined the frequencies of T cell subsets and their cytokine profiles. Both cohorts included patients who underwent primary resection and patients who received neoadjuvant chemotherapy followed by surgical resection. RESULTS: In human PDAC, T cells were particularly enriched within the tumor stroma. Neoadjuvant chemotherapy markedly enhanced T cell density within the ductal area of the tumor. Whereas infiltration of cytotoxic CD8(+) T cells was unaffected by neoadjuvant chemotherapy, the frequency of conventional CD4(+) T cells was increased, and the proportion of Tregs was reduced in the pancreatic tumor microenvironment after neoadjuvant treatment. Moreover, neoadjuvant chemotherapy increased the production of proinflammatory cytokines by tumor-infiltrating T cells, with enhanced TNF-α and IL-2 and reduced IL-4 and IL-10 expression. CONCLUSION: Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile. Combinational treatment strategies incorporating immunotherapy in neoadjuvant regimens may unleash more effective antitumor responses and improve prognosis of pancreatic cancer. FUNDING: This work was supported by the Jung Foundation for Science and Research, the Monika Kutzner Foundation, the German Research Foundation (SE2980/5-1), the German Cancer Consortium, and the Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden.
format Online
Article
Text
id pubmed-9746809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-97468092022-12-15 Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer Heiduk, Max Plesca, Ioana Glück, Jessica Müller, Luise Digomann, David Reiche, Charlotte von Renesse, Janusz Decker, Rahel Kahlert, Christoph Sommer, Ulrich Aust, Daniela E. Schmitz, Marc Weitz, Jürgen Seifert, Lena Seifert, Adrian M. JCI Insight Clinical Medicine BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally advanced and borderline resectable PDAC. The effects of neoadjuvant chemotherapy on the cytokine production of tumor-infiltrating T cells are unknown in PDAC. METHODS: We performed multiplex immunofluorescence to investigate T cell infiltration in 91 patients with PDAC. Using flow cytometry, we analyzed tumor and matched blood samples from 71 patients with PDAC and determined the frequencies of T cell subsets and their cytokine profiles. Both cohorts included patients who underwent primary resection and patients who received neoadjuvant chemotherapy followed by surgical resection. RESULTS: In human PDAC, T cells were particularly enriched within the tumor stroma. Neoadjuvant chemotherapy markedly enhanced T cell density within the ductal area of the tumor. Whereas infiltration of cytotoxic CD8(+) T cells was unaffected by neoadjuvant chemotherapy, the frequency of conventional CD4(+) T cells was increased, and the proportion of Tregs was reduced in the pancreatic tumor microenvironment after neoadjuvant treatment. Moreover, neoadjuvant chemotherapy increased the production of proinflammatory cytokines by tumor-infiltrating T cells, with enhanced TNF-α and IL-2 and reduced IL-4 and IL-10 expression. CONCLUSION: Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile. Combinational treatment strategies incorporating immunotherapy in neoadjuvant regimens may unleash more effective antitumor responses and improve prognosis of pancreatic cancer. FUNDING: This work was supported by the Jung Foundation for Science and Research, the Monika Kutzner Foundation, the German Research Foundation (SE2980/5-1), the German Cancer Consortium, and the Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden. American Society for Clinical Investigation 2022-11-22 /pmc/articles/PMC9746809/ /pubmed/36509285 http://dx.doi.org/10.1172/jci.insight.152761 Text en © 2022 Heiduk et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Medicine
Heiduk, Max
Plesca, Ioana
Glück, Jessica
Müller, Luise
Digomann, David
Reiche, Charlotte
von Renesse, Janusz
Decker, Rahel
Kahlert, Christoph
Sommer, Ulrich
Aust, Daniela E.
Schmitz, Marc
Weitz, Jürgen
Seifert, Lena
Seifert, Adrian M.
Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title_full Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title_fullStr Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title_full_unstemmed Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title_short Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer
title_sort neoadjuvant chemotherapy drives intratumoral t cells toward a proinflammatory profile in pancreatic cancer
topic Clinical Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746809/
https://www.ncbi.nlm.nih.gov/pubmed/36509285
http://dx.doi.org/10.1172/jci.insight.152761
work_keys_str_mv AT heidukmax neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT plescaioana neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT gluckjessica neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT mullerluise neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT digomanndavid neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT reichecharlotte neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT vonrenessejanusz neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT deckerrahel neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT kahlertchristoph neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT sommerulrich neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT austdanielae neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT schmitzmarc neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT weitzjurgen neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT seifertlena neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer
AT seifertadrianm neoadjuvantchemotherapydrivesintratumoraltcellstowardaproinflammatoryprofileinpancreaticcancer